Pacira Biosciences (NASDAQ:PCRX) Target Raised by Northland Securities to $54.00

0
45
stock_market_daily_information
Business or finance concept : Asia Pacific stock market data and candle stick graph chart on monitor

Pacira Biosciences stock has undergone multiple analysts rating changes in the recent past.  Pacira Biosciences stock Target Raised by   Northland Securities on 6/30/2020. In a note to investors, the firm issued a new target price of $54.00. The analysts previously had $50.00 target price. Northland Securities’s price target would indicate a potential upside of 22.48% from the stock’s previous close.

Shares of Pacira Biosciences traded up $0.52 on Tuesday, reaching $52.54. 314189 shares of the stock traded hands, compared to its average volume of 655711. Shares of were trading at $52.54 on Tuesday. The firm’s 50 day moving average is $$43.69 and its 200 day moving average is $41.73.Pacira Biosciences  has a 12 month low of $51.06 and a 12 month high of $53.05. While on yearly highs and lows, Pacira Biosciences today has traded high as $53.05 and has touched $51.06 on the downward trend.

Pacira Biosciences Earnings and What to expect: 

Pacira Biosciences last announced its earnings results on May 7th, 2020. The reported $0.53 earnings per share for the quarter, topping analysts’ consensus estimates of $0.30 by $0.23. The business had revenue of $105.68 million for the quarter, compared to analysts’ expectations of $101.64 million. Its revenue for the quarter was up 15.7% on a year-over-year basis. Pacira Biosciences has generated $0.86 earnings per share over the last year. Pacira Biosciences has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, August 13th, 2020 based off prior year’s report dates.

Earnings for Pacira Biosciences are expected to grow by 93.68% in the coming year, from $0.95 to $1.84 per share. The P/E ratio of Pacira Biosciences is -2,581.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Pacira Biosciences is -2,581.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Pacira Biosciences has a PEG Ratio of 2.22. PEG Ratios above 1 indicate that a company could be overvalued. Pacira Biosciences has a P/B Ratio of 6.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 6.20%
  • On 6/8/2020 CEO David M Stack Sell 17,111 at average share price of $48.12 which equates to $823,381.32 in money value.
  • On 6/4/2020 CFO Charles A Reinhart III Sell 1,489 at average price of  $46.33 with total value of : Not Data Available
  • On 6/4/2020 SVP Charles Anthony Laranjeira Sell 863 at average price of  $46.33 with total value of : $39,982.79
  • See More Analyst Rating at: RATING

Other Analyst’s rating for Pacira Biosciences

  • 5/29/2020 – Pacira Biosciences was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 5/27/2020 – Pacira Biosciences was downgraded by analysts at Northland Securities from an “outperform” rating to a “market perform” rating.
  • 5/26/2020 – Pacira Biosciences is now covered by analysts at Guggenheim. They set a “neutral” rating on the stock.
  • 5/13/2020 – Pacira Biosciences had its “buy” rating re-affirmed by analysts at Royal Bank of Canada. They now have a $56.00 price target on the stock.
  • See More Analyst Rating at: RATING

Other rating updates by Northland Securities: 

  • 6/30/2020 – Benefytt Technologies had its “buy” rating re-affirmed by analysts at Northland Securities. They now have a $40.00 price target on the stock.
  • 6/29/2020 – ZIX had its price target raised by analysts at Northland Securities from $9.00 to $11.00. They now have an “outperform” rating on the stock.
  • 6/26/2020 – Zogenix is now covered by analysts at Northland Securities. They set a “buy” rating and a $65.00 price target on the stock.
  • 6/26/2020 – Euronet Worldwide is now covered by analysts at Northland Securities. They set a “buy” rating and a $125.00 price target on the stock.
  • See More Analyst Rating at: RATING

Pacira Biosciences (NASDAQ:PCRX) Moving Average Technical Analysis

5 day Moving Average is $$47.56 And 5 day price change is $5.07 (11.00%)  with average volume for 5 day average is 1,033,984. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $46.08 and 20 day price change is $7.51 (17.24%) and average 20 day moving volume is 681,186. 50 day moving average is $43.69  and 50 day price change is $12.69 ( 33.06%)  and with average volume for 50 days is : 629,350. 200 day moving average is $41.73  and 200 day price change is $12.94 (33.93%)  and with average volume for 200 days is : 670,674.

See More Analyst Rating at: RATING